Novelix-Pharmaceuticals (6)
| Date | Circular | Tags | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
16,61,000 equity shares of Novelix Pharmaceuticals Limited listed on BSE effective January 1, 2026, issued through preferential allotment … | |||||||||||||||
16,61,000 equity shares of Novelix Pharmaceuticals Limited listed on BSE effective January 1, 2026, issued through preferential allotment via warrant conversion.
| |||||||||||||||
Novelix Pharmaceuticals Limited lists 15,45,000 new equity shares issued at Rs. 20/- on preferential basis pursuant to warrant conversion, … | |||||||||||||||
Novelix Pharmaceuticals Limited lists 15,45,000 new equity shares issued at Rs. 20/- on preferential basis pursuant to warrant conversion, with lock-in periods up to June 2027.
| |||||||||||||||
15,45,000 equity shares of Novelix Pharmaceuticals Limited (Scrip Code 536565) issued at Rs. 20/- on preferential basis pursuant to warrant … | |||||||||||||||
15,45,000 equity shares of Novelix Pharmaceuticals Limited (Scrip Code 536565) issued at Rs. 20/- on preferential basis pursuant to warrant conversion, listed and permitted to trade from November 27, 2025.
| |||||||||||||||
Novelix Pharmaceuticals Limited lists 15,45,000 equity shares issued at Rs. 20/- on preferential basis pursuant to conversion of warrants, … | |||||||||||||||
Novelix Pharmaceuticals Limited lists 15,45,000 equity shares issued at Rs. 20/- on preferential basis pursuant to conversion of warrants, with lock-in periods until June 2026 and 2027.
| |||||||||||||||
BSE circular detailing the listing of new equity shares for Novelix Pharmaceuticals Limited with lock-in periods. | |||||||||||||||
BSE circular detailing the listing of new equity shares for Novelix Pharmaceuticals Limited with lock-in periods.
| |||||||||||||||
BSE listing details for new equity shares of Novelix Pharmaceuticals Limited with lock-in periods. | |||||||||||||||
BSE listing details for new equity shares of Novelix Pharmaceuticals Limited with lock-in periods.
| |||||||||||||||